Europe

Actelion to cut jobs, refocus R&D

Friday, July 13, 2012 03:17 PM

Switzerland-based Actelion has launched a cost saving initiative as an integral part of its strategy for value creation outlined in early May. The initiative will cut up to 135 positions and refocusing the company’s R&D activities toward orphan and specialty indications to generate additional specialty franchises, enabling it to fully capitalize on the significant growth opportunities in its core area of expertise of pulmonary arterial hypertension (PAH).

More... »

Calixar, Synthelis to provide unique membrane protein services

Friday, July 6, 2012 01:51 PM

Calixar, a French company that isolates and crystallizes native and functional membrane proteins, and Synthelis, a French company specializing in the production and vectorization of these same molecules, have entered into an alliance for the production and isolation of all types of target membrane proteins.

More... »

Prosonix, Imperial College London collaborate on engineered combo respiratory meds

Thursday, July 5, 2012 02:43 PM

Prosonix, a speciality pharmaceutical company of Oxford, U.K., has signed a collaborative research agreement with Imperial College London to accelerate the development of engineered multi-component particles (MCPs) as respiratory medicines.

More... »

Concern as NHS spending on advanced medicines to decline

Tuesday, July 3, 2012 02:29 PM

A new forecast by the Office of Health Economics, for the ABPI, has shown that total National Health Service (NHS) spending on medicines is well under control, while expenditure on innovative branded medicines is actually set to shrink in real terms and as a proportion of the healthcare budget over the next three years.

More... »

Medicyte coordinates E.U.-funded collaboration on biomimetic bioartificial liver

Tuesday, July 3, 2012 01:57 PM

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa have launched a European-wide project, the Re-liver Consortium, aimed to design a biomimetic bioartificial liver.

More... »

Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

Tuesday, July 3, 2012 11:06 AM

Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

More... »

Dyadic Netherlands to develop enzymes for E.U.-funded research consortium

Monday, July 2, 2012 11:49 AM

Dyadic International, a global biotechnology company focused on enzymes and other proteins, announced that its R&D center in the Netherlands, a member of the multidisciplinary research consortium Bio-Mimetic Project, has been awarded a $4.4 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities.

More... »

Theradiag acquires Prestizia and microRNA technology platform

Monday, July 2, 2012 11:31 AM

Theradiag, a French theranostics and in vitro diagnostics company focused on autoimmune disease, has decided to acquire Prestizia, a French biotechnology company that develops microRNA technology.

More... »

BioInvent reorganizes after TB-402 bust

Friday, June 29, 2012 12:53 PM

BioInvent International, a Swedish research-based pharmaceutical company that focuses on developing antibody drugs, has decided to initiate negotiations with trade unions regarding organizational changes due to halting development of the antithrombotic agent TB‑402.

More... »

Shire’s VPRIV shows significant improvement in Gaucher-related bone disease

Friday, June 29, 2012 12:38 PM

Shire, a global specialty biopharmaceutical company based in Dublin, released new data that show VPRIV (velaglucerase alfa for injection), the company’s enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients.

More... »